Chimerix Inc. scrapped testing of its experimental antiviral in Ebola patients in Liberia, saying the number of infections had dropped in recent weeks, and that only a handful of patients had been enrolled in the Liberian study.
WSJ.com: Africa, Wall Street Journal: World: Africa
Sat, 01/31/2015 - 2:18pm
Chimerix Inc. scrapped testing of its experimental antiviral in Ebola patients in Liberia, saying the number of infections had dropped in recent weeks, and that only a handful of patients had been enrolled in the Liberian study.